Todd Golub (TRG) currently serves as a scientific advisor to Anji Oncology, with compensation consisting of cash and equity. He is a scientific advisor to GlaxoSmithKline, plc; this was previously a compensated engagement but is now unpaid (as of January 2021). He is a co-founder of (and holds equity in) Sherlock Biosciences, Inc., and was previously a scientific advisor to the company.
TRG is also affiliated with a number of non-profit organizations, serving on the Board of Directors of the Damon Runyon Cancer Research Foundation, the Board of Trustees of the Boston Symphony Orchestra, and the Scientific Advisory Board of the Ontario Institute for Cancer Research.
TRG may receive honoraria and travel reimbursements for speaking engagements and other activities. He is a co-inventor on patents related to his research, some of which have been licensed to companies, including those listed above.
TRG receives research funding for his laboratory from Bayer HealthCare, Novo Holdings, and Calico Life Sciences.
These policies are available at: